U.S., Sept. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07819136) titled 'REC-7735 in Participants With Solid Tumors' on Sept. 08.
Brief Summary: The study is designed to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor activity of REC-7735 in participants with unresectable, locally advanced, or metastatic PIK3CA-H1047R mutated solid tumors.
Study Start Date: Sept., 2026
Study Type: INTERVENTIONAL
Condition:
Solid Tumors
Intervention:
DRUG: REC-7735
Oral
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Recursion Pharmaceuticals Inc.
Published by HT Digital Content Services with permission from Health Daily Digest....